A CDK2 activity signature predicts outcome in CDK2-low cancers.
about
Cdk2 strengthens the intra-S checkpoint and counteracts cell cycle exit induced by DNA damage.Identification of CDK2 as a novel target in treatment of prostate cancer.Wilms' tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability.Rb is required for retinal angiogenesis and lamination.
P2860
A CDK2 activity signature predicts outcome in CDK2-low cancers.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
A CDK2 activity signature predicts outcome in CDK2-low cancers.
@en
A CDK2 activity signature predicts outcome in CDK2-low cancers.
@nl
type
label
A CDK2 activity signature predicts outcome in CDK2-low cancers.
@en
A CDK2 activity signature predicts outcome in CDK2-low cancers.
@nl
prefLabel
A CDK2 activity signature predicts outcome in CDK2-low cancers.
@en
A CDK2 activity signature predicts outcome in CDK2-low cancers.
@nl
P2093
P2860
P356
P1433
P1476
A CDK2 activity signature predicts outcome in CDK2-low cancers.
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2016.409
P407
P50
P577
2016-11-07T00:00:00Z